Business Wire

VERISILICON

4.3.2024 08:01:29 CET | Business Wire | Press release

Share
VeriSilicon’s industry-leading embedded GPU IP powers HPMicro’s high-performance HPM6800 series RISC-V MCU

VeriSilicon (688521.SH) today announced that HPMicro’s HPM6800 series, a new generation digital dashboard display and human-machine interface system application platform has adopted VeriSilicon’s high-performance 2.5D Graphics Processor Unit (GPU) IP.

HPM6800 series is based on RISC-V CPU cores, featuring robust computing power, low power consumption, high integration, and outstanding multimedia capabilities. It is the ideal solution for applications requiring complex graphics processing, high-resolution display and high-performance multimedia user interfaces, such as automotive dashboard, Human-Machine Interface (HMI), and Camera Monitor System (CMS).

VeriSilicon’s 2.5D GPU IP, which supports OpenVG, can provide MCU/MPU devices with high-efficiency graphics processing and high-quality image output while significantly reducing CPU load. With its proven scalability, it has been widely used in leading automotive, industrial, and wearable products. Additionally, VeriSilicon has collaborated with leading GUI software service providers to enrich the ecosystem for key GPU applications, effectively accelerating the market launch process for customer products.

“The HPM6800 series represents another innovation and breakthrough in our existing high-performance MCU product line,” said Jintao Zeng, CEO of HPMicro. “By integrating VeriSilicon’s advanced 2.5D GPU IP, HPM6800 not only inherits the strong computing power, precise control, and excellent communication performances of our existing MCU products, but also integrates efficient graphics processing, high-resolution display and other multimedia capabilities. We look forward to more industrial and automotive system solutions equipped with the HPM6800 high-performance MCUs.”

“This collaboration combines VeriSilicon’s rich-featured and low-power 2.5D GPU IP with HPMicro’s high-performance RISC-V based MCU, aiming to jointly launch leading products to address the growing market opportunities in the display field,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “Over the past decade, VeriSilicon’s 2.5D GPU IP has been widely used in many leading automotive and industrial products. We look forward to introducing this mature graphics processing technology into the RISC-V ecosystem to meet a wider range of customer needs.”

About HPMicro

HPMicro is a Chinese semiconductor company dedicated to offering high-performance MCUs and embedded solutions, with business involving microcontrollers, microprocessors, chipsets, as well as its supporting development tools and ecosystems. Founded in June 2020, the company’s headquartered in Shanghai, and has branches in Tianjin, Shenzhen, Suzhou and Hangzhou. At present, the company has completed ISO 9001 quality management certification and ISO 26262/IEC 61508 functional safety management system certification, fully serving the industrial, automotive and energy markets in China and the world. For more information, please visit our website https://hpmicro.com/

About VeriSilicon

VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240303801487/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal5.6.2026 07:00:00 CEST | Press release

Phase 2 RAINBOW study data showed that treatment with nizubaglustat in patients with GM2 gangliosidosis (GM2) and Niemann-Pick type C disease (NPC) reduced disease progression and seizure burdenTopline results from the study announced in 2024 demonstrated that nizubaglustat was safe and well tolerated, with encouraging signs of efficacyThe published data further supports the two ongoing registrational Phase 3 studies with nizubaglustat in GM1/GM2 and NPC Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced the publication of clinical data from its Phase 2 (RAINBOW) study in the peer reviewed journal, Molecular Genetics & Metabolism. The published manuscript reports efficacy, safety, pharmacokinetic and pharmacodynamic data which evaluated nizubaglustat in patients with genetically confirmed GM2 gangliosidosis and NPC. As previously stated in the topline results announcemen

K-Startup Grand Challenge 2026: Korea's Full-Cycle Launchpad for Global Startups5.6.2026 03:00:00 CEST | Press release

KSGC 2026 provides end-to-end support - from market entry to sustainable growth - positioning Korea as the gateway for Asia expansion South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for the K-Startup Grand Challenge (KSGC), the country’s premier government-backed acceleration program for international startups targeting Korea and Asia. Since 2016, KSGC has attracted 21,537 applicants from more than 100 countries, among the world's most recognized inbound programs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604794426/en/ South Korea’s Ministry of SMEs and Startups (MSS) has opened applications for K-Startup Grand Challenge 2026, a government-backed global startup acceleration program providing end-to-end support for international startups (Image: KSGC) A Full-Cycle Acceleration Journey Unlike conventional programs that focus on a single moment of market entry, KSGC 2026 guides startups from ma

Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More4.6.2026 23:46:00 CEST | Press release

The Empire State Building Observation Deck (ESB) – the #1 Attraction in the United States – today announced further 2026 programming for soccer fans in New York City with the world’s most iconic jersey collection from the Classic Football Shirts (CFS) vault, a limited-edition ESB x CFS jersey, official merch giveaways, and special lightings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260604370013/en/ Empire State Building Observation Deck Celebrates Soccer with World’s Most Iconic Soccer Jersey Exhibit, Custom ESB Jerseys, Player Visits, Lightings, and More “As the world descends upon New York City for this anticipated global soccer event, fans can visit the Empire State Building Observation Deck for Manhattan’s best skyline views and a one-of-a-kind soccer exhibit,” said Dan Rogoski, observatory general manager. “International and American soccer fans can extend the celebration off the pitch at the #1 Attraction in the

Vycellix to Provide Universal Cell Cancer Therapy Progress Reports at Upcoming Investor & Partnering Meetings4.6.2026 20:15:00 CEST | Press release

- June events include USA trade mission to Norway (Oslo), the EHA Annual Meeting (Stockholm) and BIO International Convention (San Diego) Vycellix, Inc., a biotechnology company developing next-generation allogeneic natural killer (NK) cell-based therapies designed to overcome the risk of immune rejection and redefine functional persistence with durability, today announced the Company will attend a series of upcoming investor and partnering meetings to share progress reports on the Company’s universal cell therapy platforms and product candidates targeting multiple myeloma, acute myeloid leukemia and urothelial cancers. Vycellix is attending: June 8-9: U.S. Department of Commerce Certified Trade Mission to Norway in Oslo June 11-14: European Hematology Association (EHA) 2026 Congress in Stockholm June 22-25: BIO International Convention in San Diego (Florida Pavilion, Booth# 1319) To request a meeting with Vycellix at any of these events, please contact Doug Calder at dcalder@vycellix.

Sodali & Co Appoints Fabio Bianconi as Head of Italy4.6.2026 19:15:00 CEST | Press release

Sodali & Co, the leading global capital markets-centric stakeholder advisory firm, today announced the appointment of Fabio Bianconi as Head of Italy, effective immediately. Fabio succeeds Andrea Di Segni, who will transition into a new role as Senior Relationship Advisor, where he will continue to support key client relationships and strategic initiatives across the firm. Fabio brings deep experience, strong client relationships, and a track record advising on complex mandates in the Italian market. He will lead Sodali’s continued growth and development in Italy, building on the firm’s established position in the region. Aneliya Crawford, Chief Partnerships Officer & Global Head of Shareholder Advisory of Sodali & Co, said: “Andrea has played a central role in the evolution of Sodali over more than two decades, helping establish the firm as a trusted global advisor in corporate governance and shareholder engagement. He built our Italian business into a leader in the market, as reflect

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye